WO2023180802A1 - Dry powder inhalation (dpi) formulation - Google Patents
Dry powder inhalation (dpi) formulation Download PDFInfo
- Publication number
- WO2023180802A1 WO2023180802A1 PCT/IB2022/060025 IB2022060025W WO2023180802A1 WO 2023180802 A1 WO2023180802 A1 WO 2023180802A1 IB 2022060025 W IB2022060025 W IB 2022060025W WO 2023180802 A1 WO2023180802 A1 WO 2023180802A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- lactose
- range
- ivermectin
- mass
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 238000009472 formulation Methods 0.000 title claims abstract description 83
- 239000000843 powder Substances 0.000 title claims abstract description 53
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 96
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 96
- 229960002418 ivermectin Drugs 0.000 claims abstract description 96
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 54
- 239000008101 lactose Substances 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 35
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 208000025721 COVID-19 Diseases 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 24
- 230000008569 process Effects 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract description 2
- 102000005548 Hexokinase Human genes 0.000 description 51
- 108700040460 Hexokinases Proteins 0.000 description 46
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 42
- 230000003993 interaction Effects 0.000 description 41
- 229960001375 lactose Drugs 0.000 description 41
- 241000700159 Rattus Species 0.000 description 35
- 210000004072 lung Anatomy 0.000 description 19
- 238000003032 molecular docking Methods 0.000 description 19
- 239000003446 ligand Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000011369 resultant mixture Substances 0.000 description 12
- 239000002775 capsule Substances 0.000 description 10
- 102100029242 Hexokinase-2 Human genes 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100030338 Hexokinase-1 Human genes 0.000 description 6
- 101001050577 Homo sapiens Kinesin-like protein KIF2A Proteins 0.000 description 6
- 101001083189 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Hexokinase-1 Proteins 0.000 description 6
- 101000840634 Oryza sativa subsp. japonica Hexokinase-5 Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 231100000706 no observed effect level Toxicity 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 150000002402 hexoses Chemical class 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710198391 Hexokinase-1 Proteins 0.000 description 3
- 101710198385 Hexokinase-2 Proteins 0.000 description 3
- 206010023203 Joint destruction Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical group O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 229940122084 Hexokinase inhibitor Drugs 0.000 description 2
- 102100029236 Hexokinase-3 Human genes 0.000 description 2
- 102100029237 Hexokinase-4 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007816 calorimetric assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010016675 Filariasis lymphatic Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101150110818 HK2 gene Proteins 0.000 description 1
- 101710198398 Hexokinase-3 Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000037263 Lymphatic filariasis Diseases 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 101710144121 Non-structural protein 5 Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000517307 Pediculus humanus Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 208000020329 Zika virus infectious disease Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000005239 filarial elephantiasis Diseases 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 230000006545 glycolytic metabolism Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011312 in silico drug discovery Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000003177 ocular onchocerciasis Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 208000009920 trichuriasis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present disclosure relates to a dry powder inhalation (DPI) formulation.
- DPI dry powder inhalation
- DIO refers to the portion of particles with diameters below the specified value is 10%.
- D50 refers to the portion of particles with diameters smaller and larger than a specified value are 50%. Also known as the median diameter.
- D90 refers to the portion of particles with diameters below the specified value is 90%.
- MMAD mass median aerodynamic diameter
- FPF Frine-particle fraction
- Vero cells refer to mammalian cell lines derived from the kidney of an African green monkey extensively used in virology studies and other applications.
- First pass metabolism refers to a phenomenon in which a drug gets metabolized at a specific location in the body that results in a reduced concentration of the active drug upon reaching its site of action or the systemic circulation.
- Binding free energy refers to the sum of all the intermolecular interactions that is present between the ligand and the target.
- Therapeutically effective amount refers to an amount of drug when administered to a subject for treating a disease, is sufficient to provide the intended therapeutic effect.
- Ivermectin is an FDA-approved broad spectrum anti-parasitic drug found to be active against various parasite infestations including head lice, scabies, river blindness, strongyloidiasis, trichuriasis, ascariasis, heartworm and lymphatic filariasis. It also shows anti-viral activity against a broad range of viruses like Dengue, West Nile, Yellow fever and Zika.
- the drug inhibits the viral replication by inhibiting the human immunodeficiency virus (HIV-1) via the integrase enzyme, through inhibition of nonstructural protein 5, a polymerase for viral RNA synthesis and regulator for immune signaling of Dengue virus, and via DNA polymerase inhibition for herpesvirus, Yellow fever virus, Dengue virus and West Nile virus via nonstructural protein 3 (a DNA helicase enzyme).
- HIV-1 human immunodeficiency virus
- nonstructural protein 5 a polymerase for viral RNA synthesis and regulator for immune signaling of Dengue virus
- Ivermectin Considering the COVID pandemic, absence of any approved medication for effective management and treatment, Ivermectin was preferred based on the available safety and efficacy details. Conventionally available oral formulations for COVID-19 requires a high oral dosage leading to poor compliance of the patients. Further, the oral administration of Ivermectin is also associated with adverse reactions that include severe episodes of confusion, ataxia, seizures, coma and hypotension including nausea, vomiting, diarrhea, an asymptomatic increase of blood uric acid and transaminases, a decrease in the neutrophil counts, and increased levels of liver enzymes such as ALT and AST.
- An object of the present disclosure is to provide a dry powder inhalation (DPI) formulation.
- Another object of the present disclosure is to provide a dry powder inhalation formulation of Ivermectin.
- An object of the present disclosure is to provide a dry powder inhalation formulation that avoids the first-pass metabolism.
- Another object of the present disclosure is to provide a dry powder inhalation formulation that exerts equivalent/enhanced efficacy at a reduced dose.
- Still another object of the present disclosure is to provide a simple process for the preparation of a dry powder inhalation formulation.
- the present disclosure relates to a dry powder inhalation (DPI) formulation and a process for its preparation.
- DPI dry powder inhalation
- the dry powder inhalation formulation comprises a micronized Ivermectin having a particle size in the range of 0.1 pm to 5 pm; a first lactose having a particle size in the range of 10 pm to 200 pm; a second lactose having a particle size in the range of 1 pm to 150 pm, and optionally at least one excipient.
- the mass ratio of the first lactose to the second lactose is in the range of 5:1 to 15:1.
- the process for the preparation of dry powder inhalation formulation comprises blending of a first lactose and a second lactose to obtain a lactose mixture.
- the lactose mixture was sifted through 80 mesh to obtain a homogeneous lactose mixture.
- the homogeneous lactose mixture is divided into two portions i.e. a first portion (-75%) and a second portion (-25%).
- At least one additive is mixed with the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture.
- a predetermined amount of Ivermectin is mixed with the second portion of the homogenous lactose mixture to obtain a mixture and the mixture is sifted through 80 mesh to obtain a second resultant mixture.
- the first resultant mixture and the second resultant mixture are blended at a speed in the range of 10 rpm to 30 rpm for a time period in the range of 10 minutes to 60 minutes to obtain the dry powder inhalation (DPI) formulation.
- the so obtained dry powder inhalation (DPI) formulation is loaded into size 3 HPMC capsules by using a capsule filler.
- Figure 1A illustrates a graph depicting cumulative (% undersize) particle size distribution of the dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg in accordance with the present disclosure
- Figure IB illustrates a graph depicting drug deposition of the dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg in accordance with the present disclosure
- Figure 1C illustrates a graph depicting cumulative (% undersize) particle size distribution of the dry powder inhalation (DPI) formulation of Ivermectin 1.7 mg in accordance with the present disclosure
- Figure ID illustrates a graph depicting drug deposition of the dry powder inhalation (DPI) formulation of Ivermectin 1.7 mg in accordance with the present disclosure
- Figure 2A illustrates a molecular docking of Ivermectin Bia binding with hexokinase I along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
- Figure 2B illustrates a molecular docking of Ivermectin Bib binding with hexokinase I along with 3D model of the interactions and the 2D interaction patterns without H-bond interaction;
- Figure 2C illustrates a molecular docking of Ivermectin Bia binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
- Figure 2D illustrates a molecular docking of Ivermectin Bib binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
- Figure 2E illustrates a molecular docking of 2-Deoxy-D-Glucose (2DG) binding with hexokinase I (PDB ID: 1CZA) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction
- Figure 2F illustrates a molecular docking of 2-Deoxy-D-Glucose (2DG) binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
- Figure 3 illustrates a graphical representation of percentage hexokinase inhibition activity of Ivermectin against control and 2-deoxy-2 glucose (2DG);
- Figure 4 illustrates a molecular docking of mitogen-activated protein kinase 1 binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance;
- Figure 4A illustrates a molecular docking of cellular tumor antigen P53 binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance;
- Figure 4B illustrates a molecular docking of RAC-alpha serine/threonine -protein kinase binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance.
- Embodiments are provided so as to thoroughly and fully convey the scope of the present disclosure to the person skilled in the art. Numerous details, are set forth, relating to specific components, and methods, to provide a complete understanding of embodiments of the present disclosure. It will be apparent to the person skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the present disclosure. In some embodiments, well-known processes, well-known apparatus structures, and well-known techniques are not described in detail.
- Ivermectin Considering the COVID pandemic, absence of any approved medication for effective management and treatment, Ivermectin was preferred based on the available safety and efficacy details. Conventionally available oral formulations for COVID-19 requires a high oral dosage leading to poor compliance of the patients. Further, the oral administration of Ivermectin is also associated with adverse reactions that include mild to moderate diarrhea, an asymptomatic increase of blood uric acid and transaminases, a decrease in the neutrophil counts, and increased levels of liver enzymes such as ALT and AST.
- the present disclosure provided a dry powder inhalation (DPI) formulation and a process for its preparation.
- DPI dry powder inhalation
- the dry powder inhalation (DPI) formulation comprises:
- the micronized Ivermectin is in an amount in the range of 1 mass% to 15 mass% with respect to the total mass of the formulation.
- the first lactose is in an amount in the range of 70 mass% to 90 mass% with respect to the total mass of the formulation.
- the mean particle size (dlO) of the first lactose is in the range of 10 pm to 50pm.
- the mean particle size (d50) of the first lactose is in the range of 51 pm to 120 pm. In an embodiment, the mean particle size (d90) of the first lactose is in the range of 121 pm to 200 pm.
- the second lactose is in an amount in the range of 5 mass% to 15 mass% with respect to the total mass of the formulation.
- the mean particle size (dlO) of the second lactose is in the range of 1 pm to 30 pm.
- the mean particle size (d50) of the second lactose is in the range of 31 pm to 90 pm.
- the mean particle size (d90) of the second lactose is in the range of 91 pm to 150 pm.
- the mass ratio of the first lactose to the second lactose is in the range of 5:1 to 15:1. In the exemplary embodiment of the present disclosure, the mass ratio of first lactose to second lactose is 9.1:1.
- the MMAD of the dry powder inhalation is in the range of 1.5 pm to 2.5 pm.
- the excipient is in an amount in the range of 1 mass% to 5 mass% with respect to the total mass of the formulation.
- the excipient is selected from citric acid monohydrate, magnesium stearate.
- a first lactose and a second lactose are blended to obtain the lactose mixture.
- the lactose mixture is sifted through 80 mesh in a controlled temperature and humidity conditions to obtain a homogeneous lactose mixture.
- the homogeneous lactose mixture is divided into two portions i.e. a first portion (-75%) and a second portion (-25%).
- additive is mixed with the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture.
- Ivermectin is mixed with the second portion of the homogenous lactose mixture to obtain a mixture, the mixture is sifted through 80 mesh size to obtain the second resultant mixture.
- the first resultant mixture and the second resultant mixture are blended at a speed of 10 rpm to 30 rpm for a time period in the range of 10 minutes to 60 minutes to obtain the dry powder inhalation (DPI) formulation.
- DPI dry powder inhalation
- the so obtained dry powder inhalation (DPI) formulation is loaded into size 3 HPMC (Hydroxypropyl methylcellulose) capsules using a capsule filler.
- the present disclosure provides the dry powder inhalation formulation that avoids the first- pass metabolism.
- the formulation of the present disclosure is therapeutically effective at a reduced dose and also observed increased patient compliance. Further, the dry powder inhalation formulation of the present disclosure has been evaluated for its toxicity on rats. It is observed that the No Observed Effect Level (NOEL) of Ivermectin is >0.27 mg a.i./kg b.wt. when administered through inhalation for up to 2 weeks.
- NOEL No Observed Effect Level
- the dose of Ivermectin as a DPI is almost 7 fold less than the oral dose; hence the use of Ivermectin as a DPI is beneficial to avoid such allergic reactions and side effects observed with oral treatment.
- the formulation of the present disclosure is used for in the treatment of cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases.
- the formulation of the present disclosure is used for in the treatment of lung cancer, COVID- 19 infection and rheumatoid arthritis.
- a method for treating cancer preferably lung cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases in mammals, the method comprises administering a therapeutically effective amount of dry powder inhalation (DPI) formulation at a dose in the range of 0.375mg/dose/day to 1.7 mg/dose/day.
- DPI dry powder inhalation
- the mammal is human.
- the cancer is lung cancer.
- the autoimmune disease is rheumatoid arthritis.
- the viral infection is COVID-19 infection.
- the dry powder inhalation (DPI) formulation is used for the treatment of cancer, preferably lung cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases.
- a first lactose (respitose SV003) and 2.3 mg of a second lactose (respitose ML006) were mixed using double lined polybags and sifted using 80 mesh size to obtain a homogeneous lactose mixture.
- the homogeneous lactose mixture was divided into two portions i.e. a first portion (-75%) and a second portion (-25%). 0.25 mg of citric acid monohydrate was added to the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture.
- Ivermectin particle size of NMT 5.0 microns
- the first resultant mixture and the second resultant mixture are transferred to a double cone blender and blended at a speed of 30 rpm for a time period in the range of 45 minutes to obtain the dry powder inhalation (DPI) formulation of Ivermectin (Formulation 1).
- DPI dry powder inhalation
- the dry powder inhalation formulations were prepared in the similar manner as disclosed in Example 1, by varying the concentration of ingredients according to the formulations as illustrated in Table 1.
- the so obtained dry powder inhalation formulation was filled into a size 3 HPMC capsule using a capsule filler.
- Aerodynamic Particle Size Distribution (APSD), delivered dose, are the critical quality attributes for the in vitro characterization of orally inhaled drug products (OINDPs).
- the APSD of an aerosol determines the portion of DPI particles that deposit in the body especially in the lower respiratory tract.
- the particles in the range of 1 to 5 microns reach the lower respiratory tract are considered effective, particles with larger than 5 microns will remain in the upper respiratory tract and are likely to impact the oropharynx and be swallowed, particles smaller than 1 micron will be cleared by lungs clearance mechanism.
- Dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg was evaluated for Aerodynamic Particle Size Distribution (APSD).
- the APSD from each dose of the dry powder inhalation formulation of the present disclosure was evaluated using Next Generation Impactor (NGI).
- NGI Next Generation Impactor
- the instrument was loaded with content of the 0.375 mg capsule of the dry powder formulation of Ivermectin 0.325mg, the flow rate through the instrument during testing was regulated at 0.74 L/minute. The procedure was repeated for Ivermectin 1.7 mg.
- the dry powder inhalation formulation collected in the filter was analyzed for Ivermectin content in lungs, fine particle fraction, MMAD, and geometric standard deviation (GSD), results are provided below in Table 4.
- the cumulative (% undersize) particle size distribution, drug deposition for Ivermectin 0.375mg and Ivermectin 1.7 mg were illustrated in Fig. 1A, IB, 1C, and ID respectively.
- Example 5 In-vivo toxicity studies of the Dry Powder Inhalation formulation of the present disclosure
- the toxicity of the dry powder inhalation formulation of the present disclosure was evaluated in Wistar rats to determine the No Observed Effect Level (NOEL).
- NOEL No Observed Effect Level
- the study animals (24) (6 rats/sex/group) were divided into two groups, control (GI) administered with only air, intervention (Gill) was administered Ivermectin at a dose of 0.27 mg/kg body weight once daily for 14 days.
- the Ivermectin was loaded in the rotating brush generator and dust was generated.
- the Ivermectin DPI was loaded, in a cylindrical powder reservoir of the aerosol generator system, positioned below the cylindrical brush.
- the airflow rate through the dust generator was maintained approximately at 39 litres per minute for GI and Gill respectively. Rats belonging to GI were exposed for 15 minutes and rats belonging to Gill were exposed for 11 minutes.
- the mean delivered doses were 0.27 mg a.i./kg b. wt. for Ivermectin (mean measured value).
- the mass median aerodynamic diameter (MMAD) of Ivermectin aerosols was found within a range of 3.15 and 3.33 pm with a geometric standard deviation (GSD) within a range of 1.61 and 1.65.
- the animals were observed daily for clinical signs, morbidity, and mortality.
- the body weight is recorded at regular intervals on day 1 (before treatment), day 4, day 8, and day 15.
- the feed consumption was calculated on day 4, day 8, and day 15.
- the rats were euthanized using thiopentone sodium overdose, followed by pathological examination.
- the pathological examination includes external abnormalities, followed by euthanization, organs were removed intact, examined, and weighed.
- the organ weights of the left lung, liver, kidneys, spleen, adrenals, heart, testes, epididymides, ovaries, uterus with cervix, thymus, and brain were recorded. Further, the broncho-alveolar lavage (BAL) of the right lung was analyzed.
- BAL broncho-alveolar lavage
- MMAD mass median aerodynamic diameter
- rats were treated with dry powder inhalation formulation of the present disclosure, showed 42.032 to 99.457 ng/mL of Ivermectin in plasma for male rats and 62.481 to 125.265 ng/mL of Ivermectin in plasma for female rats and 55.888 to 180.562 ng/gram of Ivermectin in lungs of male rats and 104.666 to 180.562 ng/gram of Ivermectin in lungs of female rats.
- the Ivermectin concentration in the lungs after 14 days of administration is at least 3 fold excess to the IC50 dose of A549 human lung cancer cell lines, indicating the possibility of potent efficacy of the developed formulation in the treatment of lung cancer, when administered as a dry powder inhalation.
- the No Observed Effect Level (NOEL) of Ivermectin was >0.27 mg a.i./kg b. wt., when administered through inhalation up to 2 weeks in Wistar rats under the procedure and conditions followed in this study. The detailed observations for each of the parameters are provided below i. Signs of Toxicity
- Rats were observed twice each day in the duration of the experimental period for morbidity and mortality (before and after exposure on treatment days, and morning and evening on non-treatment days). Observations include evaluation of skin and fur, eyes, mucous membranes, respiratory and circulatory effects, autonomic and central nervous system effects, somatomotor activity and behaviour pattern, and observation of tremor, convulsions, salivation, diarrhoea, lethargy, sleep, and coma. In addition, rats were observed for the detailed clinical signs once daily along with the above observations. Rats were also observed for clinical signs at the end of exposure and one -hour post exposure. ii. Body Weight
- the individual body weight for each rat was recorded on the day of randomization (prior to treatment), 1 (beginning of the treatment), and on days 4, 7, and at 15 (study termination).
- Table 6 Body Weight (g) of Individual Rat (Group GUI)
- Table 7 Percent Body Weight Change of Individual Rat (Group GI)
- the feed consumption of animals was calculated on day 4, day 8, and day 15.
- the weekly feed consumption for each rat was calculated throughout the study using the below formula.
- the rats were administered with 0.27 mg/kg body weight of the dry powder inhalation formulation of Ivermectin in accordance with the present disclosure.
- the rat plasma was obtained on the 14 th day of administration, the concentration of Ivermectin in the plasma was evaluated by LC-MS/MS. 1. Instrumental Parameters
- Table 11 indicate the parameters for detection of Ivermectin using multiple reaction monitoring (MRM) through targeted mass spectrometry (MS) technique.
- MRM multiple reaction monitoring
- MS targeted mass spectrometry
- the concentration of Ivermectin in the lung homogenate was calculated using the formula below,
- the broncho-alveolar lavage was obtained from the right lung after euthanized by barbiturate overdose followed by exsanguination at scheduled sacrifices (day 15). The lavage was analyzed for cellular contents, the details are illustrated below in Table 14; TABLE 14: Broncho- Alveolar Lavage Analysis - Group Mean Values
- the rats were euthanized by barbiturate overdose, organs were removed intact, examined, and weighed. Organ weights of left lungs, liver, kidneys, spleen, adrenals, heart, testes, epididymides, thymus, ovaries, uterus with cervix, and brain were taken. All organs were preserved in 10% neutral buffered formalin solution except testes which was preserved in Modified Davidson’s fixative. The organ weights of treated groups (Gill) were compared well with the control group (GI), the results are illustrated below in Table 15. TABLE 15: Organ Weight (g) - Group Mean Values
- the molecular docking study was performed by AutoDock 4.2.6 program, using the implemented empirical free energy function and the Lamarckian Genetic Algorithm (LG A).
- Molecular Docking is an important component of computer-assisted drug discovery. It helps in predicting the intermolecular framework formed between a protein and ligand and outputs the appropriate binding between the molecules. The best conformation with the lowest docked energy was chosen from the docking search.
- Pymol software is a cross-platform molecular graphics tool widely used for three-dimensional (3D) visualization of Proteins and Ligands, UCSF Chimera and Accelrys Discovery Studio Visualizer software.
- the binding energy between the target (protein) and the ligand was calculated. Higher the value of free binding energy, the higher the requested energy to break that binding between two molecules. So, the negative values show a related binding between protein and ligand. Very negative score corresponds to a strong binding and a less negative or even positive score corresponds to a weak or non-existing binding.
- RA rheumatoid arthritis
- MAPKs mitogen-activated protein kinases
- the p53 tumor suppressor is abnormal in the synovial lining of RA, giving rise to the hypothesis that the p53-dependent apoptosis pathway is defective in RA and when overexpressed early, may ameliorate the course of the arthritis disease.
- AKT1 and the related AKT2 are activated by platelet-derived growth factors.
- AKT is a serine/threonine kinase that supports proliferation and survival in a variety of cells and is overexpressed in the rheumatoid synovial tissue.
- Mitogen-activated protein kinase 1 MAPK1
- (1WZY) TP53 Cellular Tumor Antigen P53 (2BIN)
- Example 7 Comparison of In-vitro activity of Ivermectin against 2-Deoxy-2-glucose (2DG) in COVID-19 by inhibiting hexokinase In-vitro activity of formulation of the present disclosure was investigated against 2-Deoxy-2- glucose in COVID-19 by inhibiting hexokinase.
- Ivermectin acts as a potential hexokinase inhibitor.
- a Hexokinase is an enzyme that phosphorylates hexoses (six-carbon sugars), forming hexose phosphate. In most organisms, glucose is the most important substrate for hexokinases, and glucose-6-phosphate is the most important product. All hexokinases are capable of phosphorylating several hexoses but glucokinase acts with 50-fold lower substrate affinity and its main hexose substrate is glucose.
- Hexokinases have been found in every organism ranging from bacteria, yeast, and plants, to humans and other vertebrates. They are grouped as actin fold proteins, sharing a common ATP binding site core and surrounded by more variable sequences that determine substrate affinities. In mammalian tissues, there are four major hexokinases which are HK1, HK2, HK3, and HK4. HK1 and HK2 are the main hexokinases that have contribution in cell survival. Mammalian adult tissues mostly expressed HK1 isoform, while HK2 is present abundantly only in adult tissues such as cardiac muscles, skeletal, and adipose.
- a Hexokinase II also known as HK2 is an enzyme which in humans is encoded by the HK2 gene on chromosome 2. This gene encodes hexokinase 2, the predominant form found in skeletal muscle. It localizes to the outer membrane of mitochondria. Expression of this gene is insulin- responsive, and in rat it is involved in the increased rate of glycolysis seen in rapidly growing cancer cells.
- HK2 is one of four highly homologous hexokinase isoforms in mammalian cells. HK2 is highly expressed in several cancers, including breast cancer and colon cancer. Due to their action HK helps in promoting cancer cell growth through an increased glycolytic flux.
- HK-I high-density polystyrene
- HK-II high-density polystyrene
- HK-III high-density polystyrene-maleic anhydride-se
- Hypoxia increased the steady-state levels of HK-II mRNA but did not increase the steady-state levels of HK-I.
- any molecule that will inhibit hexokinase would reduce the hyper-expressed HK and hence might address hypoxia state.
- the infected viral cells require glycolysis and other associated pathways to gain substrates for their function and replication.
- glycolysis can be target of interest.
- HK inhibition contributes to this apoptosis through intrinsic pathway that includes destabilization of mitochondrial complexes and also interfering with glycolysis results in autophagy.
- Hexokinase kit was purchased from Sigma Aldrich (Product no: MAK91, Bangalore, India). 2-Deoxy-2-glucose, purchased from Sigma Aldrich (Bangalore, India). Other chemicals such as Ivermectin from Hoster biotech Pvt ltd were procured for the study.
- Hexokinase assay The hexokinase (HK) assay was carried out by using hexokinase calorimetric assay kit (Sigma-Aldrich, MAK091). NADH standard solution from HK assay kit was reconstituted with 400 pl water to generate 1.25 mM stock solution. From stock solution, 0, 2, 4, 6, 8, 10 pl aliquots were withdrawn into 96 well plate to achieve blank, 2.5, 5, 7.5, 10 and 12.5 nmol/well concentrations. One unit of HK is the amount of enzyme that will generate 1.0 molc of NADH per minute at pH 8.0 at room temperature. To each well 50 pL of sample solution containing inhibitor solution and HK enzyme was added followed by 50 pL of appropriate reaction mix.
- the HK activity of a sample was determined by the following equation
- B Amount (nmole) of NADH generated between Tj njtiai and Tf ina i.
- V sample volume (mL) added to well
- hexokinase calorimetric assay kit Sigma-Aldrich, MAK091.
- Reagent control for each solvent or diluent in which inhibitor solution was prepared was also kept to investigate the effect on hexokinase activity.
- the inhibitor stock solutions were diluted in hexokinase assay buffer to get final volume of 50 pl with known units of hexokinase enzyme.
- the control reaction was carried out in hexokinase assay buffer without addition of any inhibitor solution or solvent.
- the relative hexokinase activity for each compound was calculated as per given below.
- Table no. 21 Composition of HK assay reaction mix
- the study demonstrates HK inhibition activity of various antiviral compounds by measuring % residual HK activity with and without the presence of the compounds under testing.
- This coupled enzyme assay based on conversion of glucose to glucose-6-phosphate by hexokinase, which is oxidized by glucose-6-phosphate dehydrogenase to form NADH.
- the resulting NADH reduces a colorless probe resulting in a colorimetric (450 nm) product proportional to the hexokinase activity present.
- HK inhibitory activity of Ivermectin was evaluated by detecting generation of NADH.
- the lower amount of NADH generation confirms the inhibitory potential of a compound.
- the anti-hexokinase activity of Ivermectin was compared with compound 1 i.e. 2- deoxy-2-glucose which have been proved for its HK inhibition activity and as antiviral in treatment of SARS-CoV-2.
- Ivermectin was found to be 99% more stronger hexokinase inhibitor as compared to 2DG since it has similar level of inhibition when used at ten times less concentration to 2DG The inhibition of HK will induce the apoptosis and reduce the viral cell replication. So, it is evident that Ivermectin was found to be a more potent inhibitor of hexokinase as compared to 2DG as depicted in figure 3.
- DPI dry powder inhalation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to a dry powder inhalation (DPI) formulation and a process for its preparation. The dry powder inhalation formulation comprises a micronized Ivermectin, a first lactose, a second lactose, and optionally at least one excipient. The dry powder formulation of the present disclosure increases the bioavailability of the Ivermectin, patient compliance, and reduced adverse effects.
Description
DRY POWDER INHALATION (DPI) FORMULATION
FIELD
The present disclosure relates to a dry powder inhalation (DPI) formulation.
DEFINITIONS
As used in the present disclosure, the following terms are generally intended to have the meaning as set forth below, except to the extent that the context in which they are used indicates otherwise.
DIO refers to the portion of particles with diameters below the specified value is 10%.
D50 refers to the portion of particles with diameters smaller and larger than a specified value are 50%. Also known as the median diameter.
D90 refers to the portion of particles with diameters below the specified value is 90%.
MMAD (mass median aerodynamic diameter) refers to the diameter at which 50% of the particles of an aerosol by mass are larger and 50% are smaller.
FPF (Fine-particle fraction) refers to a fraction wherein the fine particle dose is divided by the total emitted dose.
Vero cells refer to mammalian cell lines derived from the kidney of an African green monkey extensively used in virology studies and other applications.
First pass metabolism refers to a phenomenon in which a drug gets metabolized at a specific location in the body that results in a reduced concentration of the active drug upon reaching its site of action or the systemic circulation.
Binding free energy refers to the sum of all the intermolecular interactions that is present between the ligand and the target.
Therapeutically effective amount refers to an amount of drug when administered to a subject for treating a disease, is sufficient to provide the intended therapeutic effect.
BACKGROUND
The background information hereinbelow relates to the present disclosure but is not necessarily prior art.
Ivermectin is an FDA-approved broad spectrum anti-parasitic drug found to be active against various parasite infestations including head lice, scabies, river blindness, strongyloidiasis, trichuriasis, ascariasis, heartworm and lymphatic filariasis. It also shows anti-viral activity against a broad range of viruses like Dengue, West Nile, Yellow fever and Zika. The drug inhibits the viral replication by inhibiting the human immunodeficiency virus (HIV-1) via the integrase enzyme, through inhibition of nonstructural protein 5, a polymerase for viral RNA synthesis and regulator for immune signaling of Dengue virus, and via DNA polymerase inhibition for herpesvirus, Yellow fever virus, Dengue virus and West Nile virus via nonstructural protein 3 (a DNA helicase enzyme).
Considering the COVID pandemic, absence of any approved medication for effective management and treatment, Ivermectin was preferred based on the available safety and efficacy details. Conventionally available oral formulations for COVID-19 requires a high oral dosage leading to poor compliance of the patients. Further, the oral administration of Ivermectin is also associated with adverse reactions that include severe episodes of confusion, ataxia, seizures, coma and hypotension including nausea, vomiting, diarrhea, an asymptomatic increase of blood uric acid and transaminases, a decrease in the neutrophil counts, and increased levels of liver enzymes such as ALT and AST.
There is, therefore, felt a need to develop a formulation that overcomes the above-mentioned drawbacks.
OBJECTS
Some of the objects of the present disclosure, which at least one embodiment herein satisfies, are as follows.
It is an object of the present disclosure to ameliorate one or more problems of the prior art or to at least provide a useful alternative.
An object of the present disclosure is to provide a dry powder inhalation (DPI) formulation.
Another object of the present disclosure is to provide a dry powder inhalation formulation of Ivermectin.
An object of the present disclosure is to provide a dry powder inhalation formulation that avoids the first-pass metabolism.
Another object of the present disclosure is to provide a dry powder inhalation formulation that exerts equivalent/enhanced efficacy at a reduced dose.
Still another object of the present disclosure is to provide a simple process for the preparation of a dry powder inhalation formulation.
Other objects and advantages of the present disclosure will be more apparent from the following description, which is not intended to limit the scope of the present disclosure.
SUMMARY
The present disclosure relates to a dry powder inhalation (DPI) formulation and a process for its preparation.
In an aspect, the dry powder inhalation formulation comprises a micronized Ivermectin having a particle size in the range of 0.1 pm to 5 pm; a first lactose having a particle size in the range of 10 pm to 200 pm; a second lactose having a particle size in the range of 1 pm to 150 pm, and optionally at least one excipient. The mass ratio of the first lactose to the second lactose is in the range of 5:1 to 15:1.
In another aspect, the process for the preparation of dry powder inhalation formulation comprises blending of a first lactose and a second lactose to obtain a lactose mixture. The lactose mixture was sifted through 80 mesh to obtain a homogeneous lactose mixture. The homogeneous lactose mixture is divided into two portions i.e. a first portion (-75%) and a second portion (-25%). At least one additive is mixed with the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture. Separately, a predetermined amount of Ivermectin is mixed with the second portion of the homogenous lactose mixture to obtain a mixture and the mixture is sifted through 80 mesh to obtain a second resultant mixture. The first resultant mixture and the second resultant mixture are blended at a speed in the range of 10 rpm to 30 rpm for a time period in the range of 10 minutes to 60 minutes to obtain the dry powder inhalation (DPI) formulation. The so obtained
dry powder inhalation (DPI) formulation is loaded into size 3 HPMC capsules by using a capsule filler.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING
The present disclosure will now be described with the help of the accompanying drawing, in which:
Figure 1A illustrates a graph depicting cumulative (% undersize) particle size distribution of the dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg in accordance with the present disclosure;
Figure IB illustrates a graph depicting drug deposition of the dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg in accordance with the present disclosure;
Figure 1C illustrates a graph depicting cumulative (% undersize) particle size distribution of the dry powder inhalation (DPI) formulation of Ivermectin 1.7 mg in accordance with the present disclosure;
Figure ID illustrates a graph depicting drug deposition of the dry powder inhalation (DPI) formulation of Ivermectin 1.7 mg in accordance with the present disclosure;
Figure 2A illustrates a molecular docking of Ivermectin Bia binding with hexokinase I along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
Figure 2B illustrates a molecular docking of Ivermectin Bib binding with hexokinase I along with 3D model of the interactions and the 2D interaction patterns without H-bond interaction;
Figure 2C illustrates a molecular docking of Ivermectin Bia binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
Figure 2D illustrates a molecular docking of Ivermectin Bib binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
Figure 2E illustrates a molecular docking of 2-Deoxy-D-Glucose (2DG) binding with hexokinase I (PDB ID: 1CZA) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
Figure 2F illustrates a molecular docking of 2-Deoxy-D-Glucose (2DG) binding with hexokinase II (PDB: 2NZT) along with 3D model of the interactions and the 2D interaction patterns with H-bond interaction;
Figure 3 illustrates a graphical representation of percentage hexokinase inhibition activity of Ivermectin against control and 2-deoxy-2 glucose (2DG);
Figure 4 illustrates a molecular docking of mitogen-activated protein kinase 1 binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance;
Figure 4A illustrates a molecular docking of cellular tumor antigen P53 binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance; and
Figure 4B illustrates a molecular docking of RAC-alpha serine/threonine -protein kinase binding with Ivermectin shows 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance.
DETAILED DESCRIPTION
Embodiments, of the present disclosure, will now be described with reference to the accompanying drawing.
Embodiments are provided so as to thoroughly and fully convey the scope of the present disclosure to the person skilled in the art. Numerous details, are set forth, relating to specific components, and methods, to provide a complete understanding of embodiments of the present disclosure. It will be apparent to the person skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the present disclosure. In some embodiments, well-known processes, well-known apparatus structures, and well-known techniques are not described in detail.
The terminology used, in the present disclosure, is only for the purpose of explaining a particular embodiment and such terminology shall not be considered to limit the scope of the present disclosure. As used in the present disclosure, the forms "a,” "an," and "the" may be intended to include the plural forms as well, unless the context clearly suggests otherwise. The terms "comprises," "comprising," “including,” and “having,” are open ended transitional phrases and therefore specify the presence of stated features, integers, steps, operations,
elements, modules, units and/or components, but do not forbid the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The particular order of steps disclosed in the method and process of the present disclosure is not to be construed as necessarily requiring their performance as described or illustrated. It is also to be understood that additional or alternative steps may be employed.
Considering the COVID pandemic, absence of any approved medication for effective management and treatment, Ivermectin was preferred based on the available safety and efficacy details. Conventionally available oral formulations for COVID-19 requires a high oral dosage leading to poor compliance of the patients. Further, the oral administration of Ivermectin is also associated with adverse reactions that include mild to moderate diarrhea, an asymptomatic increase of blood uric acid and transaminases, a decrease in the neutrophil counts, and increased levels of liver enzymes such as ALT and AST.
The present disclosure provided a dry powder inhalation (DPI) formulation and a process for its preparation.
In an aspect of the present disclosure, the dry powder inhalation (DPI) formulation comprises:
• a micronized Ivermectin having a particle size in the range of 0.1 pm to 5 pm;
• a first lactose having a particle size in the range of 10 pm to 200 pm;
• a second lactose having a particle size in the range of 1 pm to 150 pm; and
• optionally at least one excipient.
In an embodiment, the micronized Ivermectin is in an amount in the range of 1 mass% to 15 mass% with respect to the total mass of the formulation.
In an embodiment, the first lactose is in an amount in the range of 70 mass% to 90 mass% with respect to the total mass of the formulation.
In an embodiment, the mean particle size (dlO) of the first lactose is in the range of 10 pm to 50pm.
In an embodiment, the mean particle size (d50) of the first lactose is in the range of 51 pm to 120 pm.
In an embodiment, the mean particle size (d90) of the first lactose is in the range of 121 pm to 200 pm.
In an embodiment, the second lactose is in an amount in the range of 5 mass% to 15 mass% with respect to the total mass of the formulation.
In an embodiment, the mean particle size (dlO) of the second lactose is in the range of 1 pm to 30 pm.
In an embodiment, the mean particle size (d50) of the second lactose is in the range of 31 pm to 90 pm.
In an embodiment, the mean particle size (d90) of the second lactose is in the range of 91 pm to 150 pm.
In an embodiment, the mass ratio of the first lactose to the second lactose is in the range of 5:1 to 15:1. In the exemplary embodiment of the present disclosure, the mass ratio of first lactose to second lactose is 9.1:1.
In an embodiment, the MMAD of the dry powder inhalation is in the range of 1.5 pm to 2.5 pm.
In an embodiment, the excipient is in an amount in the range of 1 mass% to 5 mass% with respect to the total mass of the formulation.
In an embodiment, the excipient is selected from citric acid monohydrate, magnesium stearate.
In another aspect of the present disclosure, there is provided a process for the preparation of the dry powder inhalation formulation.
The process is described in detail.
In a first step, a first lactose and a second lactose are blended to obtain the lactose mixture. The lactose mixture is sifted through 80 mesh in a controlled temperature and humidity
conditions to obtain a homogeneous lactose mixture. The homogeneous lactose mixture is divided into two portions i.e. a first portion (-75%) and a second portion (-25%).
In a second step, additive is mixed with the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture.
In a third step, separately, Ivermectin is mixed with the second portion of the homogenous lactose mixture to obtain a mixture, the mixture is sifted through 80 mesh size to obtain the second resultant mixture.
In a fourth step, the first resultant mixture and the second resultant mixture are blended at a speed of 10 rpm to 30 rpm for a time period in the range of 10 minutes to 60 minutes to obtain the dry powder inhalation (DPI) formulation.
The so obtained dry powder inhalation (DPI) formulation is loaded into size 3 HPMC (Hydroxypropyl methylcellulose) capsules using a capsule filler.
The present disclosure provides the dry powder inhalation formulation that avoids the first- pass metabolism. The formulation of the present disclosure is therapeutically effective at a reduced dose and also observed increased patient compliance. Further, the dry powder inhalation formulation of the present disclosure has been evaluated for its toxicity on rats. It is observed that the No Observed Effect Level (NOEL) of Ivermectin is >0.27 mg a.i./kg b.wt. when administered through inhalation for up to 2 weeks.
The dose of Ivermectin as a DPI is almost 7 fold less than the oral dose; hence the use of Ivermectin as a DPI is beneficial to avoid such allergic reactions and side effects observed with oral treatment.
In accordance with the embodiment of the present disclosure, the formulation of the present disclosure is used for in the treatment of cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases.
In a preferred embodiment of the present disclosure, the formulation of the present disclosure is used for in the treatment of lung cancer, COVID- 19 infection and rheumatoid arthritis.
In accordance with the embodiment of the present disclosure, a method for treating cancer, preferably lung cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases in mammals, the method comprises administering a therapeutically effective amount
of dry powder inhalation (DPI) formulation at a dose in the range of 0.375mg/dose/day to 1.7 mg/dose/day.
In an embodiment of the present disclosure, the mammal is human.
In an embodiment of the present disclosure, the cancer is lung cancer.
In an embodiment of the present disclosure, the autoimmune disease is rheumatoid arthritis.
In an embodiment of the present disclosure, the viral infection is COVID-19 infection.
In an embodiment of the present disclosure, the dry powder inhalation (DPI) formulation is used for the treatment of cancer, preferably lung cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases.
The foregoing description of the embodiments has been provided for purposes of illustration and is not intended to limit the scope of the present disclosure. Individual components of a particular embodiment are generally not limited to that particular embodiment, but, are interchangeable. Such variations are not to be regarded as a departure from the present disclosure, and all such modifications are considered to be within the scope of the present disclosure.
The present disclosure is further described in light of the following experiments which are set forth for illustration purpose only and not to be construed for limiting the scope of the disclosure. The following experiments can be scaled up to industrial/commercial scale and the results obtained can be extrapolated to industrial scale.
EXPERIMENTAL DETAILS
Example 1: Preparation of DPI formulation
Dry mixing:
21 mg of a first lactose (respitose SV003) and 2.3 mg of a second lactose (respitose ML006) were mixed using double lined polybags and sifted using 80 mesh size to obtain a homogeneous lactose mixture. The homogeneous lactose mixture was divided into two portions i.e. a first portion (-75%) and a second portion (-25%). 0.25 mg of citric acid monohydrate was added to the first portion of the homogenous lactose mixture and blended to obtain a first resultant mixture. Separately, 1.7 mg of Ivermectin (particle size of NMT 5.0 microns) was mixed with the second portion of the homogenous lactose mixture to obtain a
mixture and the mixture was sifted through 80 mesh to obtain a second resultant mixture. The first resultant mixture and the second resultant mixture are transferred to a double cone blender and blended at a speed of 30 rpm for a time period in the range of 45 minutes to obtain the dry powder inhalation (DPI) formulation of Ivermectin (Formulation 1). The so obtained dry powder inhalation (DPI) formulation of Ivermectin was loaded into size 3 HPMC capsules using a capsule filler.
Example 2:
The dry powder inhalation formulations were prepared in the similar manner as disclosed in Example 1, by varying the concentration of ingredients according to the formulations as illustrated in Table 1.
Example 3: Ivermectin - Stability Study
The stability conditions of Ivermectin are illustrated below in Tables 2-3.
Inference: The dry powder inhalation (DPI) formulation of Ivermectin in capsules of the present disclosure was subjected to 3 and 6 months accelerated stability testing at 25°C/60% RH and 40°C/75% RH respectively. It is evident from tables 2-3 that Ivermectin (API) is stable for a longer period of time, at 25°C/60% RH, and 40°C/75% RH conditions as there was no change in the Ivermectin content in dry powder inhalation (DPI) formulations of Ivermectin 0.375 mg and Ivermectin 1.7 mg.
The so obtained dry powder inhalation formulation was filled into a size 3 HPMC capsule using a capsule filler.
Example 4: In-vitro Lung Deposition Study
The Aerodynamic Particle Size Distribution (APSD), delivered dose, are the critical quality attributes for the in vitro characterization of orally inhaled drug products (OINDPs).
The APSD of an aerosol determines the portion of DPI particles that deposit in the body especially in the lower respiratory tract. The particles in the range of 1 to 5 microns reach the lower respiratory tract are considered effective, particles with larger than 5 microns will remain in the upper respiratory tract and are likely to impact the oropharynx and be swallowed, particles smaller than 1 micron will be cleared by lungs clearance mechanism.
Dry powder inhalation (DPI) formulation of Ivermectin 0.375 mg was evaluated for Aerodynamic Particle Size Distribution (APSD). The APSD from each dose of the dry powder inhalation formulation of the present disclosure was evaluated using Next Generation Impactor (NGI). The instrument was loaded with content of the 0.375 mg capsule of the dry powder formulation of Ivermectin 0.325mg, the flow rate through the instrument during testing was regulated at 0.74 L/minute. The procedure was repeated for Ivermectin 1.7 mg. The dry powder inhalation formulation collected in the filter was analyzed for Ivermectin content in lungs, fine particle fraction, MMAD, and geometric standard deviation (GSD), results are provided below in Table 4. The cumulative (% undersize) particle size distribution, drug deposition for Ivermectin 0.375mg and Ivermectin 1.7 mg were illustrated in Fig. 1A, IB, 1C, and ID respectively.
It is evident that irrespective of Ivermectin dose, nearly 58.680% reaches the lungs.
Example 5: In-vivo toxicity studies of the Dry Powder Inhalation formulation of the present disclosure
The toxicity of the dry powder inhalation formulation of the present disclosure was evaluated in Wistar rats to determine the No Observed Effect Level (NOEL). The potential toxicity of the formulation of the present disclosure, when administered via inhalation route for a period of 2 consecutive weeks (7 consecutive days per week), was evaluated. The study animals (24) (6 rats/sex/group) were divided into two groups, control (GI) administered with only air, intervention (Gill) was administered Ivermectin at a dose of 0.27 mg/kg body weight once daily for 14 days.
The Ivermectin was loaded in the rotating brush generator and dust was generated. The Ivermectin DPI was loaded, in a cylindrical powder reservoir of the aerosol generator system, positioned below the cylindrical brush. The airflow rate through the dust generator was maintained approximately at 39 litres per minute for GI and Gill respectively. Rats belonging to GI were exposed for 15 minutes and rats belonging to Gill were exposed for 11 minutes.
The mean delivered doses were 0.27 mg a.i./kg b. wt. for Ivermectin (mean measured value). The mass median aerodynamic diameter (MMAD) of Ivermectin aerosols was found within a range of 3.15 and 3.33 pm with a geometric standard deviation (GSD) within a range of 1.61 and 1.65.
The animals (rats) were observed daily for clinical signs, morbidity, and mortality. The body weight is recorded at regular intervals on day 1 (before treatment), day 4, day 8, and day 15. The feed consumption was calculated on day 4, day 8, and day 15.
After completion of the treatment period, the rats were euthanized using thiopentone sodium overdose, followed by pathological examination. The pathological examination includes external abnormalities, followed by euthanization, organs were removed intact, examined, and weighed. The organ weights of the left lung, liver, kidneys, spleen, adrenals, heart, testes,
epididymides, ovaries, uterus with cervix, thymus, and brain were recorded. Further, the broncho-alveolar lavage (BAL) of the right lung was analyzed.
During the study, it was observed that all the animals well-tolerated the dose and there is no mortality or any clinical signs of toxicity were observed. There was no statistical difference in the body weight, percent body weight change, and feed consumption in the treated groups when compared with that of the control group. The mass median aerodynamic diameter (MMAD) of the dry powder inhalation formulation in the form of aerosols was found within a range of 3.15 and 3.33 pm with a geometric standard deviation (GSD) within a range of 1.61 and 1.65.
In Gill, rats were treated with dry powder inhalation formulation of the present disclosure, showed 42.032 to 99.457 ng/mL of Ivermectin in plasma for male rats and 62.481 to 125.265 ng/mL of Ivermectin in plasma for female rats and 55.888 to 180.562 ng/gram of Ivermectin in lungs of male rats and 104.666 to 180.562 ng/gram of Ivermectin in lungs of female rats.
In another study*, the cytotoxic effects of Ivermectin was evaluated on the cell viability of A549 human lung cancer cell lines. A dose dependent decrease in the viability of A549 cells was observed when treated with Ivermectin at a concentration of 0.5-4 pg/mL and cell viability remained almost constant between 4-64 pg/mL concentrations. The IC50 value of Ivermectin on the A549 cell line was identified as 0.306 pg/ml (which is equivalent to 0.00034 mM).
*Karakus A., Karakus S. U., Usta F, Herdem U., Aksu S., Ozdemir F., Cukurcak M. & Citakoglu E. 2021. In vitro cytotoxic effects of some Covid- 19 drugs on lung cancer cells. Trakya Univ J Nat Sci, 22(2): 173-177, DOI: 10.23902/trkjnat.901480.
From the in vivo experimental results of the present disclosure, it is observed that the concentration of Ivermectin in the lungs of animals after 14 days of administration is on an average of 100 ng/mL (which is equivalent to 0.00011 mM).
Hence, it is evident that the Ivermectin concentration in the lungs after 14 days of administration is at least 3 fold excess to the IC50 dose of A549 human lung cancer cell lines, indicating the possibility of potent efficacy of the developed formulation in the treatment of lung cancer, when administered as a dry powder inhalation.
The No Observed Effect Level (NOEL) of Ivermectin was >0.27 mg a.i./kg b. wt., when administered through inhalation up to 2 weeks in Wistar rats under the procedure and conditions followed in this study.
The detailed observations for each of the parameters are provided below i. Signs of Toxicity
Rats were observed twice each day in the duration of the experimental period for morbidity and mortality (before and after exposure on treatment days, and morning and evening on non-treatment days). Observations include evaluation of skin and fur, eyes, mucous membranes, respiratory and circulatory effects, autonomic and central nervous system effects, somatomotor activity and behaviour pattern, and observation of tremor, convulsions, salivation, diarrhoea, lethargy, sleep, and coma. In addition, rats were observed for the detailed clinical signs once daily along with the above observations. Rats were also observed for clinical signs at the end of exposure and one -hour post exposure. ii. Body Weight
The individual body weight for each rat was recorded on the day of randomization (prior to treatment), 1 (beginning of the treatment), and on days 4, 7, and at 15 (study termination).
The details are illustrated below in Tables 5 and 6, and Tables 7 and 8.
Table 6: Body Weight (g) of Individual Rat (Group GUI)
Table 7: Percent Body Weight Change of Individual Rat (Group GI)
Inference: It is evident from tables 5 to 8 that there was no statistical difference in body weight was observed during the evaluation period. iii. Feed Consumption
The feed consumption of animals was calculated on day 4, day 8, and day 15. The weekly feed consumption for each rat was calculated throughout the study using the below formula.
Total feed input - feed left over
Feed Consumption (g/rat/day) = -
Number of rats per cage x Number of days The details of the feed consumption are illustrated below in Tables 9 and 10
Inference: It is evident from table 9 and 10 that there was no statistical difference observed in the feed consumption during the evaluation period. iv. Concentration of Ivermectin in rat plasma samples
The rats were administered with 0.27 mg/kg body weight of the dry powder inhalation formulation of Ivermectin in accordance with the present disclosure. The rat plasma was obtained on the 14th day of administration, the concentration of Ivermectin in the plasma was evaluated by LC-MS/MS. 1. Instrumental Parameters
HPLC Parameters
For Ivermectin
Instrument : LC-MS/MS [API 4000 mass spectrometer coupled with
Nexera X2 HPLC System]
Column : CSH Fluoro-phenyl, C18 (4.6 x 150 mm, 3.5pm) Flow Rate : 0.8 mL/minute
Injection Volume : 10 pL
Column Temperature : 40° C
Cooler Temperature : 10° C
Mobile phase : Methanol: 5Mm Ammonium acetate in Milli-Q water Elution mode : Binary/Isocratic
Mass Spectrometer Parameters for Multiple Reaction Monitoring (Ivermectin) are given below in table 11:
Inference: Table 11 indicate the parameters for detection of Ivermectin using multiple reaction monitoring (MRM) through targeted mass spectrometry (MS) technique.
The analysed concentration of Ivermectin is illustrated in Table 12 below: Table 12- Concentration of Ivermectin in rat plasma samples
BLQ = Below Limit of Quantification v. Concentration of Ivermectin in Rat (Lung Homogenate) samples
The Ivermectin content in the lungs was analysed by measuring the Ivermectin content in lung homogenate by using LC-MS/MS, the concentration is as illustrated in Table 13.
BLQ = Below Limit of Quantification
The concentration of Ivermectin in the lung homogenate was calculated using the formula below,
Concentration in homogenate [ng/g] = Concentration of drug in homogenate [ng/ml] /Concentration of lung in homogenate [g/ml] vi. Broncho-Alveolar Lavage Analysis
The broncho-alveolar lavage was obtained from the right lung after euthanized by barbiturate overdose followed by exsanguination at scheduled sacrifices (day 15). The lavage was analyzed for cellular contents, the details are illustrated below in Table 14; TABLE 14: Broncho- Alveolar Lavage Analysis - Group Mean Values
* = Large unstained cells
# = Lactate dehydrogenase
# = Lactate dehydrogenase
Inference: It is evident from table 14 that, the treatment by using the dry powder inhalation formulation did not lead to any treatment related alterations in broncho-alveolar lavage when compared with control. vii. Organ Weight (g) - Group Mean Values
The rats were euthanized by barbiturate overdose, organs were removed intact, examined, and weighed. Organ weights of left lungs, liver, kidneys, spleen, adrenals, heart, testes, epididymides, thymus, ovaries, uterus with cervix, and brain were taken. All organs were preserved in 10% neutral buffered formalin solution except testes which was preserved in Modified Davidson’s fixative. The organ weights of treated groups (Gill) were compared well with the control group (GI), the results are illustrated below in Table 15.
TABLE 15: Organ Weight (g) - Group Mean Values
Inference: It was observed from table 15 that, a statistically significant decrease was observed in the weight of thymus in Gill females, which was not considered as an effect of test item treatment due to lack of consistency between sexes. viii. Macroscopic findings The rats were subjected to full gross necropsy, examined for external abnormalities. The thoracic and abdominal cavities were cut, opened and organs were examined to detect abnormalities. The findings are illustrated below in Table 16.
TABLE 16: Gross Findings - Summary by Groups
Inference: The macroscopic observations on external and internal organs did not reveal any treatment related findings. However, it was noticed that the reduced size of testes and epididymides in one male rat of the control group was considered as incidental/spontaneous.
Example 6: In-silico drug discovery study of Ivermectin
The molecular docking study was performed by AutoDock 4.2.6 program, using the implemented empirical free energy function and the Lamarckian Genetic Algorithm (LG A). Molecular Docking is an important component of computer-assisted drug discovery. It helps in predicting the intermolecular framework formed between a protein and ligand and outputs the appropriate binding between the molecules. The best conformation with the lowest docked energy was chosen from the docking search. The interactions of complex proteinligand conformations including hydrogen bonds and bond lengths were analyzed using Pymol software which is a cross-platform molecular graphics tool widely used for three-dimensional (3D) visualization of Proteins and Ligands, UCSF Chimera and Accelrys Discovery Studio Visualizer software.
The binding energy between the target (protein) and the ligand was calculated. Higher the value of free binding energy, the higher the requested energy to break that binding between two molecules. So, the negative values show a related binding between protein and ligand. Very negative score corresponds to a strong binding and a less negative or even positive score corresponds to a weak or non-existing binding.
2-Deoxy-D-Glucose, IvermectinBla and IvermectinBlb as a ligands were got from the PubChem drug databases and docked against hexokinase 1 protein (PDB: 1CZA) and hexokinase II (PDB: 2NZT) with high AutoDock V4.2 software. The findings were reported below in tables 16-17 and figures 2A to 2F that shows molecular docking of Ivermectin Bia, Ivermectin Bib, and 2-deoxy-D-glucose binding with hexokinase I and II along with 3D
model of the interactions and the 2D interaction patterns and with or without H-bond interaction.
5
Inference:
On performing the molecular docking of the protein name (PDB ID: 1CZA) with all five ligands, it was observed that the binding energy of Ivermectin BIA with 1CZA is good (-6.72 kcal/mol) followed by Ivermectin BIB shows -5.77 kcal/mol and -5.57 kcal/mol respectively.
5 The study also shows the presence of H-bonds that indicates stable interaction between ligand and protein.
Inference:
On performing the molecular docking of the protein name (PDB ID: 2NZT) with all five ligands, it was observed that the binding energy of IvermectinBlA with 2NZT is good (-7.36 kcal/mol) followed by IvermectinBIB shows -6.15 kcal/mol and -6.39 kcal/mol respectively. The study also shows the presence of H-bonds that indicates stable interaction between ligand and protein.
Comparative analysis:
The molecular docking of both the proteins (PDB ID: 1CZA) and (PDB ID: 2NZT) against hexokinase I and II is analyzed and compared below in table 19:
Inference:
It is evident from table 19 that the binding energy of IvermectinB lA with (PDB ID: 1CZA- - 6.72 kcal/mol)and 2NZT is good (-7.36 kcal/mol) against hexokinase I and II respectively in comparison with 2DG has a binding energy of -3.3 kcal/mol.
Molecular docking studies of Ivermectin with 1WZY, 2BIN, 6S9X:
Since abnormal glycolytic metabolism contributes to joint inflammation and destruction in rheumatoid arthritis (RA), the present disclosure investigated the use of Ivermectin in the treatment of rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic autoimmune disease in which imbalances in pro-anti-inflammatory cytokines promote the induction of
autoimmunity, inflammation and joint destruction. Mitogen-activated protein kinases (MAPKs) have been implicated as playing key regulatory roles in the production of pro- inflammatory cytokines like IL-1, IL- 6, IL- 12, TNF and downstream signalling events leading to joint inflammation and destruction. The p53 tumor suppressor is abnormal in the synovial lining of RA, giving rise to the hypothesis that the p53-dependent apoptosis pathway is defective in RA and when overexpressed early, may ameliorate the course of the arthritis disease. AKT1 and the related AKT2 are activated by platelet-derived growth factors. AKT is a serine/threonine kinase that supports proliferation and survival in a variety of cells and is overexpressed in the rheumatoid synovial tissue. Mitogen-activated protein kinase 1 (MAPK1)- (1WZY), TP53 Cellular Tumor Antigen P53 (2BIN) and AKT1 RAC-alpha serine/threonine-protein kinase (6S9X) as a protein were got from the Protein Data Bank (PDB) with PDB ID: - 1WZY, 2BIN, 6S9X and docked against ligand Ivermectin with high AutoDock V4.2 software. The findings were reported below in table 20 and figures 4 to 4B shows molecular docking of proteins such as 1WZY, 2BIN, 6S9X binding with Ivermectin along with 3D model of the interactions and the 2D interaction patterns and H-bond interaction and ligand interaction with distance and without distance.
Inference:
On performing the molecular docking of the protein names 1WZY, 2BIN, 6S9X with Ivermectin, it was observed that the binding energy of 1WZY with Ivermectin is good (-7.16 kcal/mol) followed by 2BIN shows -6.20 kcal/mol and followed by 6S9X shows -5.95 kcal/mol respectively. The study also shows the presence of H-bonds that indicates stable interaction between ligand and protein.
Higher the value of free binding energy, the higher, and the requested energy to break that binding between two molecules. So, the negative values show a related binding between protein and ligand. A very negative score corresponds to a strong binding and a less negative or even positive score corresponds to a weak or non-existing binding. From the results, it was clear that Ivermectin could have a potential role in the alleviation of symptoms seen in rheumatoid arthritis (RA).
Example 7: Comparison of In-vitro activity of Ivermectin against 2-Deoxy-2-glucose (2DG) in COVID-19 by inhibiting hexokinase In-vitro activity of formulation of the present disclosure was investigated against 2-Deoxy-2- glucose in COVID-19 by inhibiting hexokinase.
It is clearly evident from example 6 that Ivermectin acts as a potential hexokinase inhibitor. A Hexokinase is an enzyme that phosphorylates hexoses (six-carbon sugars), forming hexose
phosphate. In most organisms, glucose is the most important substrate for hexokinases, and glucose-6-phosphate is the most important product. All hexokinases are capable of phosphorylating several hexoses but glucokinase acts with 50-fold lower substrate affinity and its main hexose substrate is glucose.
Hexokinases (HK) have been found in every organism ranging from bacteria, yeast, and plants, to humans and other vertebrates. They are grouped as actin fold proteins, sharing a common ATP binding site core and surrounded by more variable sequences that determine substrate affinities. In mammalian tissues, there are four major hexokinases which are HK1, HK2, HK3, and HK4. HK1 and HK2 are the main hexokinases that have contribution in cell survival. Mammalian adult tissues mostly expressed HK1 isoform, while HK2 is present abundantly only in adult tissues such as cardiac muscles, skeletal, and adipose. A Hexokinase II also known as HK2 is an enzyme which in humans is encoded by the HK2 gene on chromosome 2. This gene encodes hexokinase 2, the predominant form found in skeletal muscle. It localizes to the outer membrane of mitochondria. Expression of this gene is insulin- responsive, and in rat it is involved in the increased rate of glycolysis seen in rapidly growing cancer cells. HK2 is one of four highly homologous hexokinase isoforms in mammalian cells. HK2 is highly expressed in several cancers, including breast cancer and colon cancer. Due to their action HK helps in promoting cancer cell growth through an increased glycolytic flux. There are three HK isoforms expressed in the lung, HK-I, HK-II, and HK-III. Hypoxia increased the steady-state levels of HK-II mRNA but did not increase the steady-state levels of HK-I. Hence, any molecule that will inhibit hexokinase would reduce the hyper-expressed HK and hence might address hypoxia state. As far as viral infection is concern, the infected viral cells require glycolysis and other associated pathways to gain substrates for their function and replication. Studies showed that to induce cell apoptosis, glycolysis can be target of interest. HK inhibition contributes to this apoptosis through intrinsic pathway that includes destabilization of mitochondrial complexes and also interfering with glycolysis results in autophagy.
Materials and methods:
Chemicals:
Hexokinase kit was purchased from Sigma Aldrich (Product no: MAK91, Bangalore, India). 2-Deoxy-2-glucose, purchased from Sigma Aldrich (Bangalore, India). Other chemicals such as Ivermectin from Hoster biotech Pvt ltd were procured for the study.
Hexokinase assay:
The hexokinase (HK) assay was carried out by using hexokinase calorimetric assay kit (Sigma-Aldrich, MAK091). NADH standard solution from HK assay kit was reconstituted with 400 pl water to generate 1.25 mM stock solution. From stock solution, 0, 2, 4, 6, 8, 10 pl aliquots were withdrawn into 96 well plate to achieve blank, 2.5, 5, 7.5, 10 and 12.5 nmol/well concentrations. One unit of HK is the amount of enzyme that will generate 1.0 molc of NADH per minute at pH 8.0 at room temperature. To each well 50 pL of sample solution containing inhibitor solution and HK enzyme was added followed by 50 pL of appropriate reaction mix. For control samples, same procedure was followed without addition of inhibitor solution. The samples were mixed in well by pipetting. The plate was incubated in dark for 5 min at room temperature. After 5 min (Tjnjtiai) incubation, initial absorbance [(A45o)initiai] was measured at 450 nm using ELISA plate reader (Erba LisaScan II). Plate was incubated for 60 min taking measurements every 10 min. Final measurement [(A45o)fmai] and time of final reading (Tgnai) was used to calculate enzyme activity. Using these measurements, the change in measurement from Tjnjtiai to Tgnai for the samples was calculated using following formula;
AA450 = (A450)fmai - (A450)initiai
The HK activity of a sample was determined by the following equation;
B X Samole Dilution Factor
HK Activity = here (Reaction Time) X V
B = Amount (nmole) of NADH generated between Tjnjtiai and Tfinai.
Reaction Time = Tfmai - Tinitiai (minutes)
V = sample volume (mL) added to well
Screening for hexokinase inhibitors by in-vitro enzyme inhibition studies:
Screening for hexokinase inhibitors was carried out using hexokinase calorimetric assay kit (Sigma-Aldrich, MAK091). The stock solutions of 2-deoxy-2-glucose, was prepared with water whereas Ivermectin was prepared using buffer (10% DMSO+ 40% PEG 400+ 5% tween 80+ 45% saline). Reagent control for each solvent or diluent in which inhibitor solution was prepared was also kept to investigate the effect on hexokinase activity. The inhibitor stock solutions were diluted in hexokinase assay buffer to get final volume of 50 pl with known units of hexokinase enzyme. The control reaction was carried out in hexokinase assay buffer without addition of any inhibitor solution or solvent. The relative hexokinase activity for each compound was calculated as per given below.
HK activity for compounds (Inhibitors)
Relative hexokinase activity = X 100
HK activity for control
Results and conclusion:
The study demonstrates HK inhibition activity of various antiviral compounds by measuring % residual HK activity with and without the presence of the compounds under testing. This coupled enzyme assay, based on conversion of glucose to glucose-6-phosphate by hexokinase, which is oxidized by glucose-6-phosphate dehydrogenase to form NADH. The resulting NADH reduces a colorless probe resulting in a colorimetric (450 nm) product proportional to the hexokinase activity present.
In this study, HK inhibitory activity of Ivermectin was evaluated by detecting generation of NADH. The lower amount of NADH generation confirms the inhibitory potential of a compound. The anti-hexokinase activity of Ivermectin was compared with compound 1 i.e. 2- deoxy-2-glucose which have been proved for its HK inhibition activity and as antiviral in treatment of SARS-CoV-2.
Ivermectin was found to be 99% more stronger hexokinase inhibitor as compared to 2DG since it has similar level of inhibition when used at ten times less concentration to 2DG The inhibition of HK will induce the apoptosis and reduce the viral cell replication. So, it is evident that Ivermectin was found to be a more potent inhibitor of hexokinase as compared to 2DG as depicted in figure 3.
TECHNICAL ADVANCES AND ECONOMIC SIGNIFICANCE
The present disclosure described hereinabove has several technical advantages including, but not limited to, the realization of a dry powder inhalation (DPI) formulation, that
• has increased bioavailability of the Ivermectin, thus reduces dosage amount when compared to the oral dosage form;
• prevents/ reduces adverse effects in comparison to the oral dosage form;
• improved patient compliance; and provides a simple and economical process for the preparation of the dry powder inhalation (DPI) formulation.
Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The use of the expression “at least” or “at least one” suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the disclosure to achieve one or more of the desired objects or results.
Any discussion of documents, acts, materials, devices, articles or the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of
the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.
The numerical values mentioned for the various physical parameters, dimensions or quantities are only approximations and it is envisaged that the values higher/lower than the numerical values assigned to the parameters, dimensions or quantities fall within the scope of the disclosure, unless there is a statement in the specification specific to the contrary.
While considerable emphasis has been placed herein on the components and component parts of the preferred embodiments, it will be appreciated that many embodiments can be made and that many changes can be made in the preferred embodiments without departing from the principles of the disclosure. These and other changes in the preferred embodiment as well as other embodiments of the disclosure will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.
Claims
1. A dry powder inhalation (DPI) formulation comprising:
• a micronized Ivermectin having a particle size in the range of 0.1 pm to 5 pm;
• a first lactose having a particle size in the range of 10 pm to 200 pm;
• a second lactose having a particle size in the range of 1 pm to 150 pm; and
• optionally at least one excipient; wherein a mass ratio of the first lactose to the second lactose is in the range of 5:1 to 15:1.
2. The formulation as claimed in claim 1, wherein said micronized Ivermectin is in an amount in the range of 1 mass% to 15 mass% with respect to the total mass of the formulation.
3. The formulation as claimed in claim 1, wherein said first lactose is in an amount in the range of 70 mass% to 90 mass% with respect to the total mass of the formulation.
4. The formulation as claimed in claim 1 , wherein said second lactose is in an amount in the range of 5 mass% to 15 mass% with respect to the total mass of the formulation.
5. The formulation as claimed in claim 1, wherein said excipient is in an amount in the range of 1 mass% to 5 mass% with respect to the total mass of the formulation.
6. The formulation as claimed in claim 1, wherein said excipient is selected from citric acid, magnesium stearate, and a combination thereof.
7. The formulation as claimed in claim 1, wherein the median mass aerodynamic diameter (MMAD) of said dry powder inhalation is in the range of 1.5 pm to 2.5 pm.
8. The formulation as claimed in claim 1, wherein the mean particle size (dlO) of said first lactose is in the range of 10 pm to 50 pm.
9. The formulation as claimed in claim 1, wherein the mean particle size (d50) of said first lactose is in the range of 51 pm to 120 pm.
10. The formulation as claimed in claim 1, wherein the mean particle size (d90) of said first lactose is in the range of 121 pm to 200 pm.
The formulation as claimed in claim 1, wherein the mean particle size (dlO) of said second lactose is in the range of 1 pm to 30 pm. The formulation as claimed in claim 1, wherein the mean particle size (d50) of said second lactose is in the range of 31 pm to 90 pm. The formulation as claimed in claim 1, wherein the mean particle size (d90) of said second lactose is in the range of 91 pm to 150 pm. The formulation as claimed in claim 1, is used for the treatment of cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases. A method of treating cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases in mammals, wherein said method comprises administering a therapeutically effective amount of dry powder inhalation (DPI) formulation as claimed in claim 1 at a dose in the range of 0.375 mg/dose/day to 1.7 mg/dose/day. The method as claimed in claim 15, wherein said mammal is human. The method as claimed in claim 15, wherein said cancer is lung cancer. The method as claimed in claim 15, wherein said autoimmune disease is rheumatoid arthritis. The method as claimed in claim 15, wherein said viral infection is COVID-19 infection. Use of the dry powder inhalation (DPI) formulation as claimed in claim 1, for the treatment of cancer, bacterial infection, viral infection, fungal infection and autoimmune diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202221017041 | 2022-03-25 | ||
IN202221017041 | 2022-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023180802A1 true WO2023180802A1 (en) | 2023-09-28 |
Family
ID=88100168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/060025 WO2023180802A1 (en) | 2022-03-25 | 2022-10-19 | Dry powder inhalation (dpi) formulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023180802A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021229514A1 (en) * | 2020-05-14 | 2021-11-18 | Orbicular Pharmaceutical Technologies Private Limited | Pharmaceutical ivermectin compositions |
-
2022
- 2022-10-19 WO PCT/IB2022/060025 patent/WO2023180802A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021229514A1 (en) * | 2020-05-14 | 2021-11-18 | Orbicular Pharmaceutical Technologies Private Limited | Pharmaceutical ivermectin compositions |
Non-Patent Citations (3)
Title |
---|
ERRECALDE J., LIFSCHITZ A., VECCHIOLI G., CEBALLOS L., ERRECALDE F., BALLENT M., MARíN G., DANIELE M., TURIC E., SPITZER E., : "Ivermectin repurposing for COVID- 19 therapy: Safety and pharmacokinetic assessment of a novel nasal spray formulation in a pig model", BIORXIV, 24 October 2020 (2020-10-24), pages 1 - 23, XP055848221, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.10.23.352831v1.full.pdf> [retrieved on 20211006], DOI: 10.1101/2020.10.23.352831 * |
LEON CALY ET AL.: "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", ANTIVIRAL RESEARCH, vol. 178, 1 June 2020 (2020-06-01), pages 104787, XP055731793, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2020.104787 * |
M. SHOUMAN ET AL.: "Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt", A RANDOMISED CLINICAL TRIAL JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, vol. 15, no. 2, February 2021 (2021-02-01), pages OC27 - OC32, XP093002449, DOI: 10.7860/JCDR/2021/46795.14529 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201904586A (en) | (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-F][1,2 , 4] triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphonium)amino)propionate crystalline form | |
JPH0466453B2 (en) | ||
US20140120181A1 (en) | Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent | |
Chu et al. | Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages | |
Zha et al. | Mitochonic acid 5 rescues cardiomyocytes from doxorubicin-induced toxicity via repressing the TNF-α/NF-κB/NLRP3-mediated pyroptosis | |
JPH11510182A (en) | Use of basic amino acids and derivatives to reduce ceramide levels | |
Luo et al. | ACT001 Ameliorates ionizing radiation-induced lung injury by inhibiting NLRP3 inflammasome pathway | |
CN115429805A (en) | An anti-FLT3-ITD drug-resistant mutant acute myeloid leukemia drug | |
CN105418599A (en) | New salt and medical use | |
WO2018092911A1 (en) | Intracellular atp enhancer | |
CN108815234A (en) | A kind of application of pharmaceutical composition in the drug of preparation treatment pulmonary disease | |
WO2023180802A1 (en) | Dry powder inhalation (dpi) formulation | |
Zhai et al. | Liposomes loaded with quercetin for resolution of lung inflammation in a lipopolysaccharide-induced mouse model of sepsis | |
EP3542823A1 (en) | Intracellular atp enhancer | |
CN108245500B (en) | Application of royal jelly acid in preparing medicine for treating diseases with increased adenosine deaminase activity | |
RU2749719C1 (en) | Drug for treatment of anemia associated with chronic kidney disease and method for its obtaining | |
WO2022224030A1 (en) | Dry powder inhalation (dpi) formulation | |
CN117062527A (en) | Terameprotocol and nordihydroguaiaretic acid (NDGA) derivatives as coronavirus antiviral agents | |
CN113244255A (en) | Application of breviscapine as medicine for preventing and treating cardiotoxicity of chemotherapeutic medicine | |
CN120114596A (en) | Compositions including SGLT inhibitors and uses thereof | |
Bielenichev et al. | The role of adipose tissue cell elements in the regulation of the nitroxidergic system and possible ways of pharmacological modulation | |
AU2013254849B2 (en) | Treatment method for steroid responsive dermatoses | |
Murthy et al. | Therapeutic properties of processed aqueous extract of Asteracantha longifolia in the human | |
RU2756312C1 (en) | Preparation for treating anemia associated with a chronic renal disease and method for production thereof | |
CN117379420B (en) | Use of aristololactam BII in preparation of leukocyte-increasing products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22933232 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22933232 Country of ref document: EP Kind code of ref document: A1 |